% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Platten:304475,
      author       = {M. Platten$^*$},
      title        = {{I}socitrate dehydrogenase mutation and microenvironment in
                      gliomas: do immunotherapy approaches matter?},
      journal      = {Current opinion in neurology},
      volume       = {nn},
      issn         = {1350-7540},
      address      = {London},
      publisher    = {Lippincott Williams $\&$ Wilkins},
      reportid     = {DKFZ-2025-01867},
      pages        = {nn},
      year         = {2025},
      note         = {#LA:D170# / epub},
      abstract     = {Gliomas with mutations in the gene for isocitrate
                      dehydrogenase (IDH) display a unique immune microenvironment
                      that is distinct from IDH-wildtype gliomas. This unique
                      immune microenvironment is shaped by 2-hydroxyglutarate
                      (2-HG), an oncometabolite produced by mutant IDH. These
                      features provide an opportunity to develop and test targeted
                      immunotherapies for IDH-mutant gliomas.IDH-mutant gliomas
                      are characterized by an immunosuppressive tumor immune
                      microenvironment (TIME) that suppresses the infiltration and
                      activation of tumor-specific T cells. This is owed both to
                      direct effects of the oncometabolite 2-hydroxyglutarate on
                      glioma-infiltrating T cells and myeloid cells and indirect
                      effects on the chemotactic profile of tumor cells. These
                      immunosuppressive effects are reversed by IDH inhibitors
                      recently approved for the treatments of IDH-mutant gliomas.
                      At the same time, clinical trials have demonstrated
                      encouraging results for targeted immunotherapies using
                      vaccines targeting the most frequent mutation IDH1R132H.The
                      reversal of the immunosuppressive effects by IDH inhibitors
                      has opened exciting avenues for combinatorial
                      immunotherapies such as vaccines and immune checkpoint
                      inhibitors.},
      subtyp        = {Review Article},
      keywords     = {glioma (Other) / immune checkpoint inhibitor (Other) /
                      immunotherapy (Other) / isocitrate dehydrogenase (Other) /
                      microenvironment (Other) / vaccine (Other)},
      cin          = {D170 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)D170-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40916936},
      doi          = {10.1097/WCO.0000000000001426},
      url          = {https://inrepo02.dkfz.de/record/304475},
}